↓ Skip to main content

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Overview of attention for article published in Blood, April 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news
2 news outlets
twitter
8 X users
patent
1 patent

Citations

dimensions_citation
205 Dimensions

Readers on

mendeley
128 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
Published in
Blood, April 2016
DOI 10.1182/blood-2016-01-694604
Pubmed ID
Authors

Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K Singhal, L Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins, Antonio Palumbo

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 128 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 14%
Other 16 13%
Student > Bachelor 16 13%
Student > Master 13 10%
Student > Ph. D. Student 11 9%
Other 21 16%
Unknown 33 26%
Readers by discipline Count As %
Medicine and Dentistry 49 38%
Biochemistry, Genetics and Molecular Biology 17 13%
Nursing and Health Professions 6 5%
Agricultural and Biological Sciences 5 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 2%
Other 11 9%
Unknown 37 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2024.
All research outputs
#1,640,728
of 25,738,558 outputs
Outputs from Blood
#1,428
of 33,549 outputs
Outputs of similar age
#26,573
of 314,398 outputs
Outputs of similar age from Blood
#39
of 264 outputs
Altmetric has tracked 25,738,558 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 33,549 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,398 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 264 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.